# Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

> **NCT00382590** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Leukemia

## Interventions

- **DRUG:** 5-Azacytidine
- **DRUG:** Ara-C
- **DRUG:** Valproic Acid (VPA)

## Key facts

- **NCT ID:** NCT00382590
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2012-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00382590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00382590, "Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00382590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*